To Advance the Developments in RNAi Therapeutics, the Developers are actively Seeking for Fundraiser

Over the years, monetary assistance from angel investors, venture capitalists, and funding schemes of various public and private organizations / funds, along with assistance from regulatory authorities, have allowed start-ups / small companies to further their R&D efforts related to the development of RNAi therapeutics.

The overall trend of investments being made in this domain has been very promising in recent years. A total of USD 5 billion has been invested in the RNAi therapeutics domain, from 2014 to 2019 (till July). It is worth highlighting that close to 60% of the total amount was invested during the time period between 2017-2019 (till July). Specifically, in 2017, companies engaged in this domain claim to have raised over USD 1.5 billion in capital investments. Examples of players that have raised capital in 2017 include (in decreasing order of capital raised) Alnylam Pharmaceuticals (USD 1,160.2 million), Ascletis Pharma (USD 100 million), Dicerna (USD 113.2 million) and Arbutus Biopharma (USD 50 million).

Companies in this domain have raised significant capital through other equity (26%), amounting to USD 381 million. Some big-ticket investments include those received by Dicerna (USD 70 million), Arbutus Biopharma (USD 66.4 million) and Silence Therapeutics (USD 58.2 million). Another popular type of funding in this domain was secondary offering, which represents 21% of the total instances; companies raised USD 2.8 billion in the given time period through such offerings.

It is worth highlighting that a number of players in this domain have managed to secure significant capital through private equity as well. In fact, we were able to identify 9 instances wherein companies received capital to fund their proprietary initiatives by means of private equity, raising an amount close to USD 587 million.

Further, we came across 6 instances of grants, which were provided by National Institutes of Health (NIH). Examples of companies that have received grants include (in decreasing order of value) miRaven and SomaGenics.

The maximum amount was raised by Alnylam Pharmaceuticals from 2014 to 2019 (till July) was approximately USD 2,300 million. It was followed by the amount raised by The Medicines, in the same time period, was approximately 964 million.

One of the key objectives of the report was to estimate the existing market size and the future growth potential within the RNAi therapeutics market, over the coming decade. Based on multiple parameters, such as target patient population, likely adoption rates and expected pricing, we have provided informed estimates on the financial evolution of the market for the period 2019-2030. The report also provides details on the likely distribution of the current and forecasted opportunity across [A] key therapeutic areas (oncological disorders, genetic disorders, metabolic disorders, hematological disorders, ophthalmic disorders and others), [B] route of administration (subcutaneous, intravenous, topical and intradermal), [C] share of leading industry players, [D] type of RNAi molecule and [E] key geographical regions (US, Europe and Asia-Pacific). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.